

**Minutes of the meeting of the AREA PRESCRIBING COMMITTEE held on
Wednesday, 11th December 2024 via MS Teams**

MEMBERS:

Erica Carmody (Chair)	Medicines Optimisation Senior Pharmacist, Strategy & Delivery Barnsley & Doncaster (SY ICB)
Chris Bland	Chair (Community Pharmacy South Yorkshire)
Patrick Cleary	Lead Pharmacist - Barnsley BDU/Medicines Information (SWYPFT)
Dr Kapil Kapur	Consultant Gastroenterologist (BHNFT)
Dr Jeroen Maters	General Practitioner (LMC)

IN ATTENDANCE:

Nicola Brazier	Medicines Optimisation Business Support Officer (SY ICB)
Joanne Howlett	Medicines Optimisation Lead Pharmacist, Strategy and Delivery Barnsley (SY ICB)
Gillian Turrell	Lead Pharmacist (BHNFT)

APOLOGIES:

Professor Adewale Adebajo	Associate Medical Director (Medicines Optimisation) on behalf of the Medical Director (BHNFT)
Deborah Cooke	Senior Pharmacist, Strategy and Delivery, Barnsley & Clinical Effectiveness (SY ICB)
Dr Mehrban Ghani	Chair, Barnsley Healthcare Federation CIC, representing the Primary Care Networks (PCNs)
Dr Madhavi Guntamukkala	Medical Director (SY ICB, Barnsley)
Chris Lawson	Programme Director for Medicines Optimisation, Strategy and Delivery (SY ICB)
Dr Munsif Mufalil	General Practitioner (LMC)
Tsz Hin Wong	Senior Interface Pharmacist (BHNFT)

**ACTION
BY**

- APC 24/204 QUORACY**
The meeting was quorate.
- APC 24/205 DECLARATIONS OF INTEREST RELEVANT TO THE AGENDA**
There were no declarations of interest relevant to the agenda to note.
- APC 24/206 DRAFT MINUTES OF THE MEETING HELD ON 13th NOVEMBER 2024**
The minutes were approved as an accurate record of the meeting.
- APC 24/207 MATTERS ARISING AND APC ACTION PLAN**
24/207.1 SCG for the prescribing of DMARDS in rheumatology patients (update) – LMC approval
The MO Lead Pharmacist, SY ICB advised at the last meeting that the LMC would like the monitoring after dose changes until patients are stable to be the responsibility of secondary care. The shared care guideline has been amended in line with the feedback from the LMC and it has been to the specialists for discussion. This has been agreed by the specialists, and secondary care will now arrange the

monitoring and prescribe for the patient during any dose changes until the patient is stable again on a new dose. Secondary care raised the issue that patients may struggle to obtain a blood test, noting that the Community Diagnostic Centre, based in the Glass Works does not have any emergency appointment slots and the phlebotomy telephone line is rarely monitored due to staffing.

The DMARD shared care now includes information regarding pregnancy in each section. The LMC asked that secondary care advise the patient to contact the consultant directly if they are pregnant or planning a pregnancy. The guideline is being finalised with these amendments and will be uploaded to the BEST website.

These updates were approved by the Committee.

24/207.2

NICE TAs (October 2024)

The Lead Pharmacist, BHNFT advised that the following NICE TA **was not** applicable for use at BHNFT: -

- TA1011 Belzutifan for treating tumours associated with von Hippel-Lindau disease

The Lead Pharmacist, BHNFT **to advise** if the following NICE TA is applicable for use at BHNFT: -

- TA1010 Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria

GT

24/207.3

Action Plan – other

Noted for information. Members to advise if any target dates need amendment.

APC 24/208

SHARED CARE GUIDELINES/AMBER G SHARED CARE GUIDELINES

No guidelines to approve this month.

APC 24/209

FORMULARY

No update this month.

APC 24/210

NEW PRODUCT LOG

Received for information.

APC 24/211

NEW PRODUCT APPLICATIONS

This item was deferred.

APC 24/212

REGIONAL MEDICINES OPTIMISATION COMMITTEE (RMOC) & SOUTH YORKSHIRE INTEGRATED MEDICINES OPTIMISATION COMMITTEE (SY IMOC)

24/212.1

SYICB IMOC Ratified Minutes – 2nd October 2024 & 6th November 2024

The minutes were shared for information.

24/212.2

SYICB IMOC Verbal Key Points – 4th December 2024

The MO Pharmacist, SY ICB provided an update from the meeting.

South Yorkshire Dementia Guideline

A form was submitted to IMOC to support discussion around the development of a South Yorkshire Dementia Guideline, suggesting a

single ICB wide amber G guideline which would replace the current Barnsley amber G guideline, which expired in December 2023. There would be no change in classification for Barnsley, the drugs would remain amber G. Feedback will be sought from the Place LMCs around support for a South Yorkshire guideline replacing Place guidance.

South Yorkshire Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of Cardiovascular Disease

This guidance was approved by IMOC, noting that the intention is to have the South Yorkshire guidance in place of the Barnsley guidance.

It was noted that the Barnsley Lipid Management for Primary Prevention for Cardiovascular Disease in Adults has recently been updated in line with the updated national summary, and the Secondary Prevention Guideline is on the APC action plan to be updated. The Barnsley guidance does include additional information such as the Barnsley traffic light classifications, local lipid clinic contact details and formulary information but it is understood that the South Yorkshire guidance will replace these.

There is no South Yorkshire Severe Hyperlipidaemia Pathway so minor changes may need to be made to the Barnsley Severe Hyperlipidaemia Pathway as it currently refers to the Barnsley guidance and it will need to refer to the South Yorkshire guidance.

Sodium zirconium cyclosilicate amber G guideline

This has been deferred and there will be further consultation with the Place LMCs.

Migraine Management in Primary Care and Rimegepant Documents

The Migraine Management document was approved clinically, with some additional wording around Rimegepant for acute migraine requested by LMCs. It was noted however that this will not be published, it will be shared again with all Place LMCs, and the use of Rimegepant in prevention of migraine has been deferred for further discussion with the LMCs. All the migraine documents will return to a future IMOC meeting.

24/212.3

IMOC approved guidelines (for information)

Links to the following guidelines, approved by IMOC were shared with the agenda for information: -

- Opioid Prescribing Resource Including Tapering Advice
- South Yorkshire Guidance for supporting women with type 2 diabetes to prepare for pregnancy
- South Yorkshire Algorithm for the management of Young Adults with Type 2 Diabetes (18-39 years)

The links have been added to the BEST website and will be added to the formulary.

APC 24/213

BARNSELY APC REPORTING

24/213.1

APC Reporting September 2024

The reports were shared for information. There were no comments received from members.

APC 24/214 NEW NICE TECHNOLOGY APPRAISALS

24/214.1 NICE TAs June 2024

The Lead Pharmacist, BHNFT confirmed the provisional 'not applicable' decision, advising that the following NICE TA **was not** applicable for use at BHNFT: -

- TA984 Tafamidis for treating transthyretin amyloidosis with cardiomyopathy

24/214.2 NICE TAs September 2024

The Lead Pharmacist, BHNFT confirmed the provisional 'not applicable' decision, advising that the following NICE TAs **were not** applicable for use at BHNFT: -

- TA1005 Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
- TA1008 Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments

24/214.3 NICE TAs November 2024

The Lead Pharmacist, BHNFT advised that the following NICE TAs **were** applicable for use at BHNFT: -

- TA1015 Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (to be delivered at The Rotherham NHS FT on behalf of Barnsley Hospital NHS FT as part of the merger of the 2 haematology departments)
- TA1018 Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis

The Lead Pharmacist, BHNFT advised that the following NICE TAs **were not** applicable for use at BHNFT: -

- TA1016 Elafibranor for previously treated primary biliary cholangitis
- TA1019 Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over
- TA1020 Eplontersen for treating hereditary transthyretin-related amyloidosis

The Lead Pharmacist, BHNFT provisionally advised that the following NICE TAs **were not** applicable for use at BHNFT: -

- TA1014 Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer
- TA1017 Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer

The Lead Pharmacist, BHNFT **to advise** if the following NICE TA is applicable for use at BHNFT: -

- TA1012 Avapritinib for treating advanced systemic mastocytosis

GT

The provisional decisions for NICE TA947, TA949, TA954, TA979, TA986, TA991 (possibly a regional decision, waiting for Sheffield and The Yorkshire Bone Network to advise), TA996, and TA1013 are still under review/yet to be confirmed by the BHNFT NICE Group, and decisions are being chased and have been escalated.

GT

- 24/214.4 Feedback from BHNFT Clinical Guidelines and Policy Group
There was nothing to report.
- 24/214.5 Feedback from SWYPFT NICE Group
There was nothing to report.
- APC 24/215 FEEDBACK FROM THE MEDICINES MANAGEMENT GROUPS**
- 24/215.1 Primary Care Quality & Cost-Effective Prescribing Group (QCEPG)
There was nothing to report.
- 24/215.2 BHNFT
There was nothing to report.
- 24/215.3 SWYPFT Drug and Therapeutics Committee (D&TC)
It was noted that SWYPFT are updating the PGD for varenicline, previously used in Barnsley, which is now a generic product. SWYPFT are working with Community Pharmacy South Yorkshire regarding its suitability following changes to the PGD, and commissioning/contracting arrangements will need to be agreed.
- 24/215.4 Community Pharmacy Feedback
There was nothing to report.
- The Chair, CPSY asked if Barnsley APC is to continue or will be part of the South Yorkshire Medicines Safety Group (previously Sheffield APG). It was noted that Barnsley APC will continue for the foreseeable future.
- Post meeting note:** The Programme Director for Medicines Optimisation, Strategy and Delivery (SY ICB) advised that Barnsley do not have a formulary group but a rolling workplan therefore this is not expected to change. The South Yorkshire Medicines Safety Group is one group across South Yorkshire and is not specific to Sheffield. To be discussed with Programme Director for Medicines Optimisation (Clinical Effectiveness, Quality and Safety) (SY ICB).*
- 24/215.5 Wound Care Advisory Group
The group have not met since the last APC, therefore there was nothing to report.
- APC 24/216 ISSUES FOR ESCALATION TO THE BARNSELY PLACE QUALITY & SAFETY COMMITTEE (JANUARY 2025)**
There were no issues to escalate to the Barnsley Place Quality and Safety Committee.
- APC 24/217 FORMULARY ACTIONS**
- 24/217.1 SPS Newsletter- October 2024
Received and noted for information.
- 24/217.2 RDTC Horizon Scanning Document – October 2024
Received and noted for information.
- 24/217.3 IMOC Horizon Scanning December 2024
The MO Lead Pharmacist, SY ICB presented enclosure K detailing the traffic light classifications agreed at the December 2024 IMOC

CL

meeting. The formulary changes for Barnsley were highlighted as follows: -

- Fruquintinib – non-formulary grey (NICE TA in development)
- Levodopa + carbidopa + entacapone – non-formulary red
- Lecanemab – non-formulary grey (NICE TA in development)
- Vamorolone - non-formulary grey (NICE TA in development)
- Somapacitan – non-formulary grey (NICE TA in development)
- Artesunate - formulary red (antimalarials for the treatment of malaria are formulary red)
- Midazolam (licence change from use only in infants, children and adolescents) – formulary amber
- Quizartinib – non-formulary red
- Vibegron – formulary green
- Elafibranor – non-formulary red

24/217.4

TLDL Sub-group List November 2024

The MO Lead Pharmacist, SY ICB presented enclosure L highlighting the formulary changes for Barnsley as follows: -

- Dexcom One + (amber G) - add as formulary amber G. Change Dexcom one to formulary amber G.
- Freestyle Libre 2+ - add a note to Freestyle Libre formulary amber G entry to say includes Freestyle Libre 2+.

The Freestyle Libre protocols will need updating to include the Freestyle Libre 2+ as it is understood Freestyle Libre 2 is to be phased out by end of August 2025 and replaced by the Freestyle Libre 2+. The improvements and additional benefits of Freestyle Libre 2+ were noted.

It was noted that IMOC have approved a CGM guideline which lists criteria for CGM. This is available on the BEST website. There is also a supporting guideline in development which details different device options and characteristics to go alongside this guideline. This will go to IMOC for approval.

- Dapsone (dual classification) (amber) - note on the formulary which says, 'for dermatological indications only' and a link to the SCG which is for dermatological indications. Add: 'Note: Dapsone is traffic lighted red for indications outside of the shared care guideline'.
- Dapsone (dual classification) (red) - note on the Barnsley Formulary which says, 'for dermatological indications only' and a link to the SCG which is for dermatological indications. Add: 'Note: Dapsone is traffic lighted red for indications outside of the shared care guideline'.
- Dalteparin (amber) - currently have a non-formulary amber G entry and a non-formulary amber entry for dalteparin. The non-formulary amber G one can be removed (we previously had formulary amber G in pregnancy prior to using tinzaparin).
- Pretomanid - add as formulary red with a link to the NHSE clinical commissioning policy.
- Daunorubicin - change from non-formulary to non-formulary red.

- Decitabine (including combinations) - currently have a non-formulary grey entry for decitabine - cedazuridine. Also add a non-formulary grey entry for decitabine.

The formulary changes were approved by the Committee.

APC 24/218 SAFETY UPDATES

24/218.1

MHRA Drug Safety Update (November 2024)

The update was noted with the following information relevant to primary care highlighted: -

MedSafetyWeek November 2024: your Yellow Card report helps prevent future harm to others and improves patient safety

The ninth annual #MedSafetyWeek social media campaign is taking place 4 to 10 November 2024. The theme for this campaign is 'preventing side effects', focusing on the importance of using healthcare products in the right way to prevent harm and reporting suspected adverse drug reactions (ADRs) to medicines and suspected adverse incidents with medical devices. We ask healthcare professionals to support the campaign and talk to their patients and colleagues about side effects and how to report suspected safety concerns to the Yellow Card scheme.

24/218.2

IMOC Safety Paper (December 2024)

The MO Lead Pharmacist, SY ICB presented the IMOC Safety Paper, and highlighted the following alerts: -

Medroxyprogesterone acetate: risk of meningioma and measures to minimise this risk

There is a small increased risk of developing meningioma with high doses of medroxyprogesterone acetate (all injectable and ≥ 100 mg oral formulations), primarily after prolonged use (several years).

For contraception or non-oncological indications, medicines containing high doses of medroxyprogesterone acetate are contraindicated in patients with a meningioma or a history of meningioma; and if meningioma is diagnosed in a patient treated with high doses of medroxyprogesterone acetate, treatment must be stopped.

MHRA recall on EXS Delay Spray Plus

LTC Healthcare has informed the MHRA that they have been selling a medicinal product containing lidocaine without authorisation from the MHRA. Patients who experience adverse reactions should be reported via the MHRA Yellow Card scheme.

Folic Acid Supplementation CAS Alert

Non-wholemeal wheat flour will be fortified with folic acid in the UK, but current UK guidelines still apply, and women who could become pregnant are advised to take a daily supplement of 400 micrograms of folic acid before conception and up until the 12th week of pregnancy.

APC 24/219 SOUTH YORKSHIRE AREA PRESCRIBING COMMITTEE MINUTES (FOR INFORMATION)

The minutes from NHS South Yorkshire ICB Doncaster Place & Bassetlaw Place Medicines Optimisation Committee (PMOC) (17th October 2024) were received and noted for information.

APC 24/220 ANY OTHER BUSINESS

24/220.1 Entreso Shared Care Guideline

The MO Pharmacist, SY ICB advised that the guideline had received a minor update, adding contact details for the Heart Failure Nurse Specialist. This has been uploaded to the BEST website.

This was endorsed by the Committee.

24/220.2 Melatonin Shared Care Guideline

The MO Pharmacist, SY ICB advised that the guideline has received another minor change in respect of the formulary position information for both Adaflex® and Melatonin 2mg MR tablets. Adaflex® tablets now says with ADHD 'or' other indications where an immediate release formulation is suitable, rather than 'and'. The melatonin MR tablets now says with ADHD but without ASD and/or Smith-Magenis syndrome. The updated guideline will be uploaded to the BEST website.

This was endorsed by the Committee.

24/220.3 Barnsley Hospital and Rotherham Adult & Paediatric Antimicrobial Guidelines and Barnsley Hospital and Rotherham Paediatric and Neonatal Antimicrobial Guidelines

The MO Pharmacist, SY ICB advised that BHNFT have informed us that these guidelines are now on the 'Eolas' platform, and that the user will be required to make an account with 'Eolas' to be able to access the platform. The user will then be required to search for the 'space' Barnsley Hospital NHS FT/The Rotherham NHS FT. Once this 'space' is added to the users account, the guidelines should be easily accessible the next time the user logs in.

It was noted that holding pages with all this information have been created on the BEST website; the links on the formulary will be updated; and the information will be included in the APC memo.

24/220.4 Shortage of Sytron Liquid

SPS information advises that if this iron salt is preferred, to prescribe generically, but to note that the generic product is a food supplement rather than a medicinal product. Or to consider alternative iron salts in liquid formulation that are medicinal products. Input will be sought from the specialists about what alternatives are being used and this information will be used to look to add suitable information to the formulary. This information will be brought back to the next APC meeting.

The Lead Pharmacist, BHNFT advised that the Trust are using SodiFer® and have switched any patients usually given Sytron Liquid to SodiFer®, which is a food supplement, but the composition is similar.

Agreed action: -

- Information about what alternatives are being used will be brought back to the next APC meeting.

JH

24/220.5

Palliative Care Stocks/Community Pharmacy Reduced Hours

The Lead Pharmacist, SWYPFT asked about contingency plans to obtain palliative care medicines in the very rare scenario where a pharmacy may be closed, with concern raised about community pharmacies reducing their opening hours.

The Lead Pharmacist, BHNFT advised that on-call was no longer resident at BHNFT but was off site, and the process and likelihood of using this contingency option would need to be looked at.

The MO Senior Pharmacist (EC), SY ICB advised that this has been raised across South Yorkshire as a concern. Considering the concern raised, this was to be added to the ICB and SWYPFT risk registers.

The Chair, CPSY to take the concerns raised with palliative care stocks and pharmacy opening hours back to the working group.

APC 24/221 DATE AND TIME OF THE NEXT MEETING

The time and date of the next meeting was confirmed as Wednesday, 8th January 2025 at 12.30 pm via MS Teams.

ADOPTED